212 related articles for article (PubMed ID: 16237164)
1. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.
Marti M; Mela F; Fantin M; Zucchini S; Brown JM; Witta J; Di Benedetto M; Buzas B; Reinscheid RK; Salvadori S; Guerrini R; Romualdi P; Candeletti S; Simonato M; Cox BM; Morari M
J Neurosci; 2005 Oct; 25(42):9591-601. PubMed ID: 16237164
[TBL] [Abstract][Full Text] [Related]
2. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
Mabrouk OS; Marti M; Morari M
Neuroscience; 2010 Mar; 166(1):40-8. PubMed ID: 20006677
[TBL] [Abstract][Full Text] [Related]
3. Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
Marti M; Rodi D; Li Q; Guerrini R; Fasano S; Morella I; Tozzi A; Brambilla R; Calabresi P; Simonato M; Bezard E; Morari M
J Neurosci; 2012 Nov; 32(46):16106-19. PubMed ID: 23152595
[TBL] [Abstract][Full Text] [Related]
4. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
Arcuri L; Viaro R; Bido S; Longo F; Calcagno M; Fernagut PO; Zaveri NT; Calò G; Bezard E; Morari M
Neurobiol Dis; 2016 May; 89():55-64. PubMed ID: 26804029
[TBL] [Abstract][Full Text] [Related]
5. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.
Marti M; Mela F; Veronesi C; Guerrini R; Salvadori S; Federici M; Mercuri NB; Rizzi A; Franchi G; Beani L; Bianchi C; Morari M
J Neurosci; 2004 Jul; 24(30):6659-66. PubMed ID: 15282268
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.
Mabrouk OS; Viaro R; Volta M; Ledonne A; Mercuri N; Morari M
J Neurosci; 2014 Sep; 34(39):12953-62. PubMed ID: 25253844
[TBL] [Abstract][Full Text] [Related]
7. NOP Receptor Ligands and Parkinson's Disease.
Mercatelli D; Pisanò CA; Novello S; Morari M
Handb Exp Pharmacol; 2019; 254():213-232. PubMed ID: 30689087
[TBL] [Abstract][Full Text] [Related]
8. Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease.
Marti M; Sarubbo S; Latini F; Cavallo M; Eleopra R; Biguzzi S; Lettieri C; Conti C; Simonato M; Zucchini S; Quatrale R; Sensi M; Candeletti S; Romualdi P; Morari M
Mov Disord; 2010 Aug; 25(11):1723-32. PubMed ID: 20589874
[TBL] [Abstract][Full Text] [Related]
9. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity.
Volta M; Viaro R; Trapella C; Marti M; Morari M
Exp Neurol; 2011 Mar; 228(1):126-37. PubMed ID: 21215744
[TBL] [Abstract][Full Text] [Related]
10. Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release.
Marti M; Mela F; Guerrini R; Calò G; Bianchi C; Morari M
J Neurochem; 2004 Dec; 91(6):1501-4. PubMed ID: 15584926
[TBL] [Abstract][Full Text] [Related]
11. Managing Parkinson's disease: moving ON with NOP.
Mercatelli D; Bezard E; Eleopra R; Zaveri NT; Morari M
Br J Pharmacol; 2020 Jan; 177(1):28-47. PubMed ID: 31648371
[TBL] [Abstract][Full Text] [Related]
12. MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons.
Gouty S; Brown JM; Rosenberger J; Cox BM
Neuroscience; 2010 Aug; 169(1):269-78. PubMed ID: 20417255
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands.
Viaro R; Calcagno M; Marti M; Borrelli E; Morari M
Neuropharmacology; 2013 Sep; 72():126-38. PubMed ID: 23643745
[TBL] [Abstract][Full Text] [Related]
14. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice.
Volta M; Mabrouk OS; Bido S; Marti M; Morari M
J Neurochem; 2010 Dec; 115(6):1543-55. PubMed ID: 20950413
[TBL] [Abstract][Full Text] [Related]
15. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
16. Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats.
Di Benedetto M; Cavina C; D'Addario C; Leoni G; Candeletti S; Cox BM; Romualdi P
Neuropharmacology; 2009 Mar; 56(4):761-7. PubMed ID: 19162046
[TBL] [Abstract][Full Text] [Related]
17. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Marti M; Trapella C; Morari M
J Neurochem; 2008 Dec; 107(6):1683-96. PubMed ID: 19014386
[TBL] [Abstract][Full Text] [Related]
18. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
Marti M; Trapella C; Viaro R; Morari M
J Neurosci; 2007 Feb; 27(6):1297-307. PubMed ID: 17287504
[TBL] [Abstract][Full Text] [Related]
19. Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs.
Gavioli EC; Calo' G
Pharmacol Ther; 2013 Oct; 140(1):10-25. PubMed ID: 23711793
[TBL] [Abstract][Full Text] [Related]
20. Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems.
Norton CS; Neal CR; Kumar S; Akil H; Watson SJ
J Comp Neurol; 2002 Mar; 444(4):358-68. PubMed ID: 11891648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
